

Keyword index

Adenosine A₁ receptor

Oedema; Adenosine A_{2B} receptor; Mast cell (Sawynok, J. (395) 47)

Adenosine A_{2B} receptor

Oedema; Adenosine A₁ receptor; Mast cell (Sawynok, J. (395) 47)

Adipocyte, white

Monoamine oxidase; Hydrogen peroxide; Cell metabolism (Raimondi, L. (395) 177)

α₁-Adrenoceptor subtype

Methoxamine; Cirazoline; P7480; Mesenteric artery, rat; BMY 7378 (Hussain, M.B. (395) 69)

γ-Aminobutyric acid (GABA)

Dopamine; Microdialysis; Cocaine; γ-Vinyl GABA (vigabatrin); γ-Aminobutyric acid (GABA) reuptake inhibitor (Gerasimov, M.R. (395) 129)

γ-Aminobutyric acid (GABA) reuptake inhibitor

γ-Aminobutyric acid (GABA); Dopamine; Microdialysis; Cocaine; γ-Vinyl GABA (vigabatrin) (Gerasimov, M.R. (395) 129)

AMPA receptor

Analgesia; NMDA receptor; Morphine; Spinal cord; (Rat) (Nishiyama, T. (395) 203)

Analgesia

NMDA receptor; AMPA receptor; Morphine; Spinal cord; (Rat) (Nishiyama, T. (395) 203)

Anesthetic

volatile; K⁺ channel; Ca²⁺-activated; *Xenopus* oocyte (Namba, T. (395) 95)

Antidepressant

Microdialysis; Serotonin (5-hydroxytryptamine, 5-HT); Selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor; Venlafaxine; YM992 (Hatanaka, K.-i. (395) 23)

Norepinephrine; 5-HT_{2A} receptor antagonist; Microdialysis; YM992; Venlafaxine (Hatanaka, K.-i. (395) 31)

Antidepressant drug

Imipramine; Lithium chloride; Locomotor activity; Mania (D'Aquila, P.S. (395) 157)

Antinociception

Locomotor activity; Straub tail; Morphine; SC17599; (Mouse) (Houshyar, H. (395) 121)

Antioxidant

Ischemia–reperfusion injury; Picroliv; Liver (Singh, A.K. (395) 229)

Antipsychotic

Neuroleptic; Catalepsy; Extrapyramidal side-effect; 5-HT (5-hydroxytryptamine, Serotonin) depletion; Dopamine D₂-like receptor; 5-HT_{1A} receptor; *p*-Chlorophenylalanine; Nemonapride; Raclopride; WAY 100635 (Prinssen, E.P.M. (395) 143)

Anti-tussive drug

Cough reflex; ATP-sensitive K⁺ channel; Moguisteine (Morita, K. (395) 161)

AP-1 (activator protein-1)

Opioid peptide; Electrophoretic mobility shift assay; Transcriptional regulation; Uterus, rat; Hypothalamus, rat (Osztér, A. (395) 103)

Arachidonic acid

Cytosolic phospholipase A₂; S-Nitroso-cysteine; cGMP; PC12 cell (Thang, S.H. (395) 183)

ATP-sensitive K⁺ channel

Cough reflex; Moguisteine; Anti-tussive drug (Morita, K. (395) 161)

Behavioural tolerance

Cannabinoid; Brain; Energetic metabolism; Cannabinoid CB₁ receptor-specific antagonist (Costa, B. (395) 1)

Bioflavonoid

P-Glycoprotein; Blood–brain barrier; Vincristine; Protein kinase C (Mitsunaga, Y. (395) 193)

Blood–brain barrier

P-Glycoprotein; Bioflavonoid; Vincristine; Protein kinase C (Mitsunaga, Y. (395) 193)

BMY 7378

α₁-Adrenoceptor subtype; Methoxamine; Cirazoline; P7480; Mesenteric artery, rat (Hussain, M.B. (395) 69)

Bradykinin

Interleukin-1β; Prostaglandin E₂; Ca²⁺ mobilization; Gingival fibroblast, human (Nakao, S. (395) 247)

Brain

Cannabinoid; Behavioural tolerance; Energetic metabolism; Cannabinoid CB₁ receptor-specific antagonist (Costa, B. (395) 1)

γ-Butyrobetaine hydroxylase inhibitor

Heart failure; Survival rate; Ventricular remodeling; Cardiac functional adaptability; High-energy phosphate (Hayashi, Y. (395) 217)

Ca²⁺-activated

Anesthetic; volatile; K⁺ channel; *Xenopus* oocyte (Namba, T. (395) 95)

Ca²⁺ mobilization

Bradykinin; Interleukin-1β; Prostaglandin E₂; Gingival fibroblast, human (Nakao, S. (395) 247)

Cannabinoid

Behavioural tolerance; Brain; Energetic metabolism; Cannabinoid CB₁ receptor-specific antagonist (Costa, B. (395) 1)

Cannabinoid CB₁ receptor-specific antagonist

Cannabinoid; Behavioural tolerance; Brain; Energetic metabolism (Costa, B. (395) 1)

Cardiac functional adaptability

γ -Butyrobetaine hydroxylase inhibitor; Heart failure; Survival rate; Ventricular remodeling; High-energy phosphate (Hayashi, Y. (395) 217)

Catalepsy

Neuroleptic; Antipsychotic; Extrapyramidal side-effect; 5-HT (5-hydroxytryptamine, Serotonin) depletion; Dopamine D₂-like receptor; 5-HT_{1A} receptor; *p*-Chlorophenylalanine; Nemonapride; Raclopride; WAY 100635 (Prinssen, E.P.M. (395) 143)

Cell metabolism

Monamine oxidase; Hydrogen peroxide; Adipocyte, white (Raimondi, L. (395) 177)

Cerebral ischemia

5-HT receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Stereology; (Rat) (Torup, L. (395) 137)

CGRP (calcitonin-gene-related peptide)

Vasodilation; Sensory nerve fibre; Migraine (Olivar, T. (395) 61)

***p*-Chlorophenylalanine**

Neuroleptic; Antipsychotic; Catalepsy; Extrapyramidal side-effect; 5-HT (5-hydroxytryptamine, Serotonin) depletion; Dopamine D₂-like receptor; 5-HT_{1A} receptor; Nemonapride; Raclopride; WAY 100635 (Prinssen, E.P.M. (395) 143)

Cirazoline

α_1 -Adrenoceptor subtype; Methoxamine; P7480; Mesenteric artery, rat; BMY 7378 (Hussain, M.B. (395) 69)

Cisapride

EM574; Motilin; Gastric emptying; (Dog) (Sako, F. (395) 165)

Clozapine-induced potentiation

NMDA receptor; MK-801; Haloperidol; Long-term potentiation; Perforant path–dentate gyrus pathway (Kubota, T. (395) 37)

Coagulation inhibitor

Thrombosis; Factor Xa; Thrombin (Sinha, U. (395) 51)

Cocaine

γ -Aminobutyric acid (GABA); Dopamine; Microdialysis; γ -Vinyl GABA (vigabatrin); γ -Aminobutyric acid (GABA) reuptake inhibitor (Gerashmov, M.R. (395) 129)

Cough reflex

ATP-sensitive K⁺ channel; Mougisteine; Anti-tussive drug (Morita, K. (395) 161)

Cyclooxygenase-1

Rheumatoid arthritis; Synoviocyte; Cyclooxygenase-2; Meloxicam (Tsubouchi, Y. (395) 255)

Cyclooxygenase-2

Rheumatoid arthritis; Synoviocyte; Cyclooxygenase-1; Meloxicam (Tsubouchi, Y. (395) 255)

Cytosolic phospholipase A₂

Arachidonic acid; *S*-Nitroso-cysteine; cGMP; PC12 cell (Thang, S.H. (395) 183)

Dermorphin N-terminal tetrapeptide

Tail-flick test; Naloxonazine; β -Funaltrexamine; μ_1 -Opioid receptor (Sakurada, S. (395) 107)

Dexamethasone

Lipopolysaccharide; Melatonin; Naltrexone; TNF- α (tumor necrosis factor- α); Nitric oxide (NO); Hyperalgesia, central/peripheral (Raghavendra, V. (395) 15)

Dopamine

Somatostatin; Subiculum; Somatostatin sst2 receptor; Microdialysis (Mitchell, S.N. (395) 43)

γ -Aminobutyric acid (GABA); Microdialysis; Cocaine; γ -Vinyl GABA (vigabatrin); γ -Aminobutyric acid (GABA) reuptake inhibitor (Gerashmov, M.R. (395) 129)

Dopamine D₂-like receptor

Neuroleptic; Antipsychotic; Catalepsy; Extrapyramidal side-effect; 5-HT (5-hydroxytryptamine, Serotonin) depletion; 5-HT_{1A} receptor; *p*-Chlorophenylalanine; Nemonapride; Raclopride; WAY 100635 (Prinssen, E.P.M. (395) 143)

Electrophoretic mobility shift assay

Opioid peptide; AP-1 (activator protein-1); Transcriptional regulation; Uterus, rat; Hypothalamus, rat (Oszter, A. (395) 103)

EM574

Motilin; Cisapride; Gastric emptying; (Dog) (Sako, F. (395) 165)

Endomorphin-1

Endomorphin-2; μ -Opioid receptor; Spontaneous alternation performance; (Mouse) (Ukai, M. (395) 211)

Endomorphin-2

Endomorphin-1; μ -Opioid receptor; Spontaneous alternation performance; (Mouse) (Ukai, M. (395) 211)

Endothelial reactivity

Hypersensitivity; Ovalbumin; Nitric oxide (NO); Pulmonary artery (Akar, F. (395) 225)

Energetic metabolism

Cannabinoid; Behavioural tolerance; Brain; Cannabinoid CB₁ receptor-specific antagonist (Costa, B. (395) 1)

Extrapyramidal side-effect

Neuroleptic; Antipsychotic; Catalepsy; 5-HT (5-hydroxytryptamine, Serotonin) depletion; Dopamine D₂-like receptor; 5-HT_{1A} receptor; *p*-Chlorophenylalanine; Nemonapride; Raclopride; WAY 100635 (Prinssen, E.P.M. (395) 143)

Factor Xa

Thrombosis; Thrombin; Coagulation inhibitor (Sinha, U. (395) 51)

Food intake

Histamine; Hypothalamus; Leptin; *Tele*-methylhistamine; (Intracerebroventricular infusion) (Lecklin, A. (395) 113)

 β -Funaltrexamine

Dermorphin N-terminal tetrapeptide; Tail-flick test; Naloxonazine; μ_1 -Opioid receptor (Sakurada, S. (395) 107)

Gastric emptying

EM574; Motilin; Cisapride; (Dog) (Sako, F. (395) 165)

Gingival fibroblast, human

Bradykinin; Interleukin-1 β ; Prostaglandin E₂; Ca²⁺ mobilization (Nakao, S. (395) 247)

P-Glycoprotein

Bioflavonoid; Blood–brain barrier; Vincristine; Protein kinase C (Mitsunaga, Y. (395) 193)

cGMP

Meloxicam; Nitric oxide (NO); N^G-L-nitro-arginine methyl ester (L-NAME); ODQ (1*H*-(1,2,4)-oxadiazolo(4,2-*a*)quinoxalin-1-one) (Aguirre-Bañuelos, P. (395) 9)

Arachidonic acid; Cytosolic phospholipase A₂; S-Nitroso-cysteine; PC12 cell (Thang, S.H. (395) 183)

H-89

Protein kinase A; Rp-cAMPS; Mitogenesis (Osinski, M.T. (395) 173)

Haloperidol

Clozapine-induced potentiation; NMDA receptor; MK-801; Long-term potentiation; Perforant path–dentate gyrus pathway (Kubota, T. (395) 37)

Heart failure

γ -Butyrobetaine hydroxylase inhibitor; Survival rate; Ventricular remodeling; Cardiac functional adaptability; High-energy phosphate (Hayashi, Y. (395) 217)

High-energy phosphate

γ -Butyrobetaine hydroxylase inhibitor; Heart failure; Survival rate; Ventricular remodeling; Cardiac functional adaptability (Hayashi, Y. (395) 217)

Histamine

Food intake; Hypothalamus; Leptin; *Tele*-methylhistamine; (Intracerebo-ventricular infusion) (Lecklin, A. (395) 113)

5-HT (5-hydroxytryptamine, Serotonin) depletion

Neuroleptic; Antipsychotic; Catalepsy; Extrapyramidal side-effect; Dopamine D₂-like receptor; 5-HT_{1A} receptor; *p*-Chlorophenylalanine; Nemonapride; Raclopride; WAY 100635 (Prinssen, E.P.M. (395) 143)

5-HT receptor

Cerebral ischemia; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetra-*lin*); Stereology; (Rat) (Torup, L. (395) 137)

5-HT_{1A} receptor

Neuroleptic; Antipsychotic; Catalepsy; Extrapyramidal side-effect; 5-HT (5-hydroxytryptamine, Serotonin) depletion; Dopamine D₂-like receptor; *p*-Chlorophenylalanine; Nemonapride; Raclopride; WAY 100635 (Prinssen, E.P.M. (395) 143)

5-HT_{2A} receptor antagonist

Norepinephrine; Microdialysis; YM992; Venlafaxine; Antidepressant (Hatanaka, K.-i. (395) 31)

Hydrogen peroxide

Monoamine oxidase; Adipocyte, white; Cell metabolism (Raimondi, L. (395) 177)

Hyperalgesia, central/peripheral

Lipopolysaccharide; Melatonin; Dexamethasone; Naltrexone; TNF- α (tumor necrosis factor- α); Nitric oxide (NO) (Raghavendra, V. (395) 15)

Hypersensitivity

Ovalbumin; Endothelial reactivity; Nitric oxide (NO); Pulmonary artery (Akar, F. (395) 225)

Hypothalamus

Food intake; Histamine; Leptin; *Tele*-methylhistamine; (Intracerebo-ventricular infusion) (Lecklin, A. (395) 113)

Hypothalamus, rat

Opioid peptide; AP-1 (activator protein-1); Electrophoretic mobility shift assay; Transcriptional regulation; Uterus, rat (Oszter, A. (395) 103)

Imipramine

Antidepressant drug; Lithium chloride; Locomotor activity; Mania (D'Aquila, P.S. (395) 157)

Interleukin-1 β

Bradykinin; Prostaglandin E₂; Ca²⁺ mobilization; Gingival fibroblast, human (Nakao, S. (395) 247)

Ischemia–reperfusion injury

Picroliv; Liver; Antioxidant (Singh, A.K. (395) 229)

K⁺ channel

Anesthetic; volatile; Ca²⁺-activated; *Xenopus* oocyte (Namba, T. (395) 95)

Leptin

Food intake; Histamine; Hypothalamus; *Tele*-methylhistamine; (Intracereboventricular infusion) (Lecklin, A. (395) 113)

Lipopolysaccharide

Melatonin; Dexamethasone; Naltrexone; TNF- α (tumor necrosis factor- α); Nitric oxide (NO); Hyperalgesia, central/peripheral (Raghavendra, V. (395) 15)

Lithium chloride

Antidepressant drug; Imipramine; Locomotor activity; Mania (D'Aquila, P.S. (395) 157)

Liver

Ischemia–reperfusion injury; Picroliv; Antioxidant (Singh, A.K. (395) 229)

Locomotor activity

Antinociception; Straub tail; Morphine; SC17599; (Mouse) (Houshyar, H. (395) 121)

Antidepressant drug; Imipramine; Lithium chloride; Mania (D'Aquila, P.S. (395) 157)

Long-term potentiation

Clozapine-induced potentiation; NMDA receptor; MK-801; Haloperidol; Perforant path–dentate gyrus pathway (Kubota, T. (395) 37)

Mania

Antidepressant drug; Imipramine; Lithium chloride; Locomotor activity (D'Aquila, P.S. (395) 157)

Mast cell

Oedema; Adenosine A₁ receptor; Adenosine A_{2B} receptor (Sawynok, J. (395) 47)

Melatonin

Lipopolysaccharide; Dexamethasone; Naltrexone; TNF- α (tumor necrosis factor- α); Nitric oxide (NO); Hyperalgesia, central/peripheral (Raghavendra, V. (395) 15)

Meloxicam

Nitric oxide (NO); cGMP; *N*^G-L-nitro-arginine methyl ester (L-NAME); ODQ (1*H*-(1,2,4)-oxadiazolo(4,2-*a*)quinoxalin-1-one) (Aguirre-Bañuelos, P. (395) 9)

Rheumatoid arthritis; Synoviocyte; Cyclooxygenase-1; Cyclooxygenase-2 (Tsubouchi, Y. (395) 255)

Mesenteric artery, rat

α_1 -Adrenoceptor subtype; Methoxamine; Cirazoline; P7480; BMY 7378 (Hussain, M.B. (395) 69)

Methoxamine

α_1 -Adrenoceptor subtype; Cirazoline; P7480; Mesenteric artery, rat; BMY 7378 (Hussain, M.B. (395) 69)

Microdialysis

Serotonin (5-hydroxytryptamine, 5-HT); Selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor; Venlafaxine; YM992; Antidepressant (Hatanaka, K.-i. (395) 23)

Norepinephrine; 5-HT_{2A} receptor antagonist; YM992; Venlafaxine; Antidepressant (Hatanaka, K.-i. (395) 31)

Somatostatin; Subiculum; Somatostatin sst2 receptor; Dopamine (Mitchell, S.N. (395) 43)

γ -Aminobutyric acid (GABA); Dopamine; Cocaine; γ -Vinyl GABA (vigabatrin); γ -Aminobutyric acid (GABA) reuptake inhibitor (Gerashimov, M.R. (395) 129)

Micturition reflex

TAK-637; Tachykinin NK₁ receptor antagonist, non-peptide; Urinary tract, lower (Doi, T. (395) 241)

Migraine

Vasodilation; Sensory nerve fibre; CGRP (calcitonin-gene-related peptide) (Olivar, T. (395) 61)

Mitogenesis

Protein kinase A; Rp-cAMPS; H-89 (Osinski, M.T. (395) 173)

MK-801

Clozapine-induced potentiation; NMDA receptor; Haloperidol; Long-term potentiation; Perforant path–dentate gyrus pathway (Kubota, T. (395) 37)

Moguisteine

Cough reflex; ATP-sensitive K⁺ channel; Anti-tussive drug (Morita, K. (395) 161)

Monoamine oxidase

Hydrogen peroxide; Adipocyte, white; Cell metabolism (Raimondi, L. (395) 177)

Morphine

Antinociception; Locomotor activity; Straub tail; SC17599; (Mouse) (Houshyar, H. (395) 121)

Analgesia; NMDA receptor; AMPA receptor; Spinal cord; (Rat) (Nishiyama, T. (395) 203)

Motilin

EM574; Cisapride; Gastric emptying; (Dog) (Sako, F. (395) 165)

Naloxonazine

Dermorphin N-terminal tetrapeptide; Tail-flick test; β -Funaltrexamine; μ_1 -Opioid receptor (Sakurada, S. (395) 107)

Naloxone benzoylhydrazone

Nocistatin; κ -Opioid receptor; Spontaneous alternation; Passive avoidance (Hiramatsu, M. (395) 149)

Naltrexone

Lipopolysaccharide; Melatonin; Dexamethasone; TNF- α (tumor necrosis factor- α); Nitric oxide (NO); Hyperalgesia, central/peripheral (Raghavendra, V. (395) 15)

Nemonapride

Neuroleptic; Antipsychotic; Catalepsy; Extrapyramidal side-effect; 5-HT (5-hydroxytryptamine, Serotonin) depletion; Dopamine D₂-like receptor; 5-HT_{1A} receptor; *p*-Chlorophenylalanine; Raclopride; WAY 100635 (Prinssen, E.P.M. (395) 143)

Neuroleptic

Antipsychotic; Catalepsy; Extrapyramidal side-effect; 5-HT (5-hydroxytryptamine, Serotonin) depletion; Dopamine D₂-like receptor; 5-HT_{1A} receptor; *p*-Chlorophenylalanine; Nemonapride; Raclopride; WAY 100635 (Prinssen, E.P.M. (395) 143)

Neuropeptide Y

Neuropeptide Y receptor; Neuropeptide Y y₆ receptor; Orexigenesis; 1229U91 (Mullins, D.E. (395) 87)

Neuropeptide Y receptor

Neuropeptide Y y₆ receptor; Neuropeptide Y; Orexigenesis; 1229U91 (Mullins, D.E. (395) 87)

Neuropeptide Y y₆ receptor

Neuropeptide Y receptor; Neuropeptide Y; Orexigenesis; 1229U91 (Mullins, D.E. (395) 87)

Nitric oxide (NO)

Meloxicam; cGMP; *N*^G-L-nitro-arginine methyl ester (L-NAME); ODQ (1*H*-(1,2,4)-oxadiazolo(4,2-*a*)quinoxalin-1-one) (Aguirre-Bañuelos, P. (395) 9)

Lipopolysaccharide; Melatonin; Dexamethasone; Naltrexone; TNF- α (tumor necrosis factor- α); Hyperalgesia, central/peripheral (Raghavendra, V. (395) 15)

PACAP (pituitary adenylate cyclase activating peptide); VIP (vasoactive intestinal peptide); Nonadrenergic noncholinergic (NANC) relaxation, inhibitory; Smooth muscle, tracheal; (Cat) (Yoshida, M. (395) 77)

Hypersensitivity; Ovalbumin; Endothelial reactivity; Pulmonary artery (Akar, F. (395) 225)

***N*^G-L-nitro-arginine methyl ester (L-NAME)**

Meloxicam; Nitric oxide (NO); cGMP; ODQ (1*H*-(1,2,4)-oxadiazolo(4,2-*a*)quinoxalin-1-one) (Aguirre-Bañuelos, P. (395) 9)

S-Nitroso-cysteine

Arachidonic acid; Cytosolic phospholipase A₂; cGMP; PC12 cell (Thang, S.H. (395) 183)

NMDA receptor

Clozapine-induced potentiation; MK-801; Haloperidol; Long-term potentiation; Perforant path–dentate gyrus pathway (Kubota, T. (395) 37)

Analgesia; AMPA receptor; Morphine; Spinal cord; (Rat) (Nishiyama, T. (395) 203)

Nocistatin

Naloxone benzoylhydrazone; κ -Opioid receptor; Spontaneous alternation; Passive avoidance (Hiramatsu, M. (395) 149)

Nonadrenergic noncholinergic (NANC) relaxation, inhibitory

PACAP (pituitary adenylate cyclase activating peptide); VIP (vasoactive intestinal peptide); Nitric oxide (NO); Smooth muscle, tracheal; (Cat) (Yoshida, M. (395) 77)

Norepinephrine

5-HT_{2A} receptor antagonist; Microdialysis; YM992; Venlafaxine; Antidepressant (Hatanaka, K.-i. (395) 31)

ODQ (1*H*-(1,2,4)-oxadiazolo(4,2-*a*)quinoxalin-1-one)

Meloxicam; Nitric oxide (NO); cGMP; *N*^G-L-nitro-arginine methyl ester (L-NAME) (Aguirre-Bañuelos, P. (395) 9)

Oedema

Adenosine A₁ receptor; Adenosine A_{2B} receptor; Mast cell (Sawynok, J. (395) 47)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin)

Cerebral ischemia; 5-HT receptor; Stereology; (Rat) (Torup, L. (395) 137)

Opioid peptide

AP-1 (activator protein-1); Electrophoretic mobility shift assay; Transcriptional regulation; Uterus, rat; Hypothalamus, rat (Oszter, A. (395) 103)

κ-Opioid receptor

Nocistatin; Naloxone benzoylhydrazone; Spontaneous alternation; Passive avoidance (Hiramatsu, M. (395) 149)

μ-Opioid receptor

Endomorphin-1; Endomorphin-2; Spontaneous alternation performance; (Mouse) (Ukai, M. (395) 211)

μ₁-Opioid receptor

Dermorphin N-terminal tetrapeptide; Tail-flick test; Naloxonazine; β-Funaltrexamine (Sakurada, S. (395) 107)

Orexigenesis

Neuropeptide Y receptor; Neuropeptide Y Y₆ receptor; Neuropeptide Y; 1229U91 (Mullins, D.E. (395) 87)

Ovalbumin

Hypersensitivity; Endothelial reactivity; Nitric oxide (NO); Pulmonary artery (Akar, F. (395) 225)

P7480

α₁-Adrenoceptor subtype; Methoxamine; Cirazoline; Mesenteric artery, rat; BMY 7378 (Hussain, M.B. (395) 69)

PACAP (pituitary adenylate cyclase activating peptide)

VIP (vasoactive intestinal peptide); Nitric oxide (NO); Nonadrenergic noncholinergic (NANC) relaxation, inhibitory; Smooth muscle, tracheal; (Cat) (Yoshida, M. (395) 77)

Passive avoidance

Nocistatin; Naloxone benzoylhydrazone; κ-Opioid receptor; Spontaneous alternation (Hiramatsu, M. (395) 149)

PC12 cell

Arachidonic acid; Cytosolic phospholipase A₂; S-Nitroso-cysteine; cGMP (Thang, S.H. (395) 183)

Perforant path–dentate gyrus pathway

Clozapine-induced potentiation; NMDA receptor; MK-801; Haloperidol; Long-term potentiation (Kubota, T. (395) 37)

Picroliv

Ischemia–reperfusion injury; Liver; Antioxidant (Singh, A.K. (395) 229)

Prostaglandin E₂

Bradykinin; Interleukin-1β; Ca²⁺ mobilization; Gingival fibroblast, human (Nakao, S. (395) 247)

Protein kinase A

Rp-cAMPS; H-89; Mitogenesis (Osinski, M.T. (395) 173)

Protein kinase C

P-Glycoprotein; Bioflavonoid; Blood–brain barrier; Vincristine (Mitsunaga, Y. (395) 193)

Pulmonary artery

Hypersensitivity; Ovalbumin; Endothelial reactivity; Nitric oxide (NO) (Akar, F. (395) 225)

Raclopride

Neuroleptic; Antipsychotic; Catalepsy; Extrapyramidal side-effect; 5-HT (5-hydroxytryptamine, Serotonin) depletion; Dopamine D₂-like receptor; 5-HT_{1A} receptor; *p*-Chlorophenylalanine; Nemonapride; WAY 100635 (Prinssen, E.P.M. (395) 143)

Rheumatoid arthritis

Synoviocyte; Cyclooxygenase-1; Cyclooxygenase-2; Meloxicam (Tsubouchi, Y. (395) 255)

Rp-cAMPS

Protein kinase A; H-89; Mitogenesis (Osinski, M.T. (395) 173)

SC17599

Antinociception; Locomotor activity; Straub tail; Morphine; (Mouse) (Houshyar, H. (395) 121)

Selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor

Microdialysis; Serotonin (5-hydroxytryptamine, 5-HT); Venlafaxine; YM992; Antidepressant (Hatanaka, K.-i. (395) 23)

Sensory nerve fibre

Vasodilation; CGRP (calcitonin-gene-related peptide); Migraine (Olivar, T. (395) 61)

Serotonin (5-hydroxytryptamine, 5-HT)

Microdialysis; Selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor; Venlafaxine; YM992; Antidepressant (Hatanaka, K.-i. (395) 23)

Smooth muscle, tracheal

PACAP (pituitary adenylate cyclase activating peptide); VIP (vasoactive intestinal peptide); Nitric oxide (NO); Nonadrenergic noncholinergic (NANC) relaxation, inhibitory; (Cat) (Yoshida, M. (395) 77)

Somatostatin

Subiculum; Somatostatin sst2 receptor; Dopamine; Microdialysis (Mitchell, S.N. (395) 43)

Somatostatin sst2 receptor

Somatostatin; Subiculum; Dopamine; Microdialysis (Mitchell, S.N. (395) 43)

Spinal cord

Analgesia; NMDA receptor; AMPA receptor; Morphine; (Rat) (Nishiyama, T. (395) 203)

Spontaneous alternation

Nocistatin; Naloxone benzoylhydrazone; κ-Opioid receptor; Passive avoidance (Hiramatsu, M. (395) 149)

Spontaneous alternation performance

Endomorphin-1; Endomorphin-2; μ -Opioid receptor; (Mouse) (Ukai, M. (395) 211)

Stereology

Cerebral ischemia; 5-HT receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); (Rat) (Torup, L. (395) 137)

Straub tail

Antinociception; Locomotor activity; Morphine; SC17599; (Mouse) (Houshyar, H. (395) 121)

Subiculum

Somatostatin; Somatostatin sst2 receptor; Dopamine; Microdialysis (Mitchell, S.N. (395) 43)

Survival rate

γ -Butyrobetaine hydroxylase inhibitor; Heart failure; Ventricular remodeling; Cardiac functional adaptability; High-energy phosphate (Hayashi, Y. (395) 217)

Synoviocyte

Rheumatoid arthritis; Cyclooxygenase-1; Cyclooxygenase-2; Meloxicam (Tsubouchi, Y. (395) 255)

Tachykinin NK₁ receptor antagonist, non-peptide

TAK-637; Micturition reflex; Urinary tract, lower (Doi, T. (395) 241)

Tail-flick test

Dermorphin N-terminal tetrapeptide; Naloxonazine; β -Funaltrexamine; μ_1 -Opioid receptor (Sakurada, S. (395) 107)

TAK-637

Tachykinin NK₁ receptor antagonist, non-peptide; Micturition reflex; Urinary tract, lower (Doi, T. (395) 241)

Tele-methylhistamine

Food intake; Histamine; Hypothalamus; Leptin; (Intracereboventricular infusion) (Lecklin, A. (395) 113)

Thrombin

Thrombosis; Factor Xa; Coagulation inhibitor (Sinha, U. (395) 51)

Thrombosis

Factor Xa; Thrombin; Coagulation inhibitor (Sinha, U. (395) 51)

TNF- α (tumor necrosis factor- α)

Lipopolysaccharide; Melatonin; Dexamethasone; Naltrexone; Nitric oxide (NO); Hyperalgesia, central/peripheral (Raghavendra, V. (395) 15)

Transcriptional regulation

Opioid peptide; AP-1 (activator protein-1); Electrophoretic mobility shift assay; Uterus, rat; Hypothalamus, rat (Oszter, A. (395) 103)

1229U91

Neuropeptide Y receptor; Neuropeptide Y y_6 receptor; Neuropeptide Y; Orexigenesis (Mullins, D.E. (395) 87)

Urinary tract, lower

TAK-637; Tachykinin NK₁ receptor antagonist, non-peptide; Micturition reflex (Doi, T. (395) 241)

Uterus, rat

Opioid peptide; AP-1 (activator protein-1); Electrophoretic mobility shift assay; Transcriptional regulation; Hypothalamus, rat (Oszter, A. (395) 103)

Vasodilation

Sensory nerve fibre; CGRP (calcitonin-gene-related peptide); Migraine (Olivar, T. (395) 61)

Venlafaxine

Microdialysis; Serotonin (5-hydroxytryptamine, 5-HT); Selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor; YM992; Antidepressant (Hatanaka, K.-i. (395) 23)

Norepinephrine; 5-HT_{2A} receptor antagonist; Microdialysis; YM992; Antidepressant (Hatanaka, K.-i. (395) 31)

Ventricular remodeling

γ -Butyrobetaine hydroxylase inhibitor; Heart failure; Survival rate; Cardiac functional adaptability; High-energy phosphate (Hayashi, Y. (395) 217)

Vincristine

P-Glycoprotein; Bioflavonoid; Blood-brain barrier; Protein kinase C (Mitsunaga, Y. (395) 193)

 γ -Vinyl GABA (vigabatrin)

γ -Aminobutyric acid (GABA); Dopamine; Microdialysis; Cocaine; γ -Aminobutyric acid (GABA) reuptake inhibitor (Gerasimov, M.R. (395) 129)

VIP (vasoactive intestinal peptide)

PACAP (pituitary adenylate cyclase activating peptide); Nitric oxide (NO); Nonadrenergic noncholinergic (NANC) relaxation, inhibitory; Smooth muscle, tracheal; (Cat) (Yoshida, M. (395) 77)

volatile

Anesthetic; K⁺ channel; Ca²⁺-activated; *Xenopus* oocyte (Namba, T. (395) 95)

WAY 100635

Neuroleptic; Antipsychotic; Catalepsy; Extrapyramidal side-effect; 5-HT (5-hydroxytryptamine, Serotonin) depletion; Dopamine D₂-like receptor; 5-HT_{1A} receptor; *p*-Chlorophenylalanine; Nemonapride; Raclopride (Prinssen, E.P.M. (395) 143)

***Xenopus* oocyte**

Anesthetic; volatile; K⁺ channel; Ca²⁺-activated (Namba, T. (395) 95)

YM992

Microdialysis; Serotonin (5-hydroxytryptamine, 5-HT); Selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor; Venlafaxine; Antidepressant (Hatanaka, K.-i. (395) 23)

Norepinephrine; 5-HT_{2A} receptor antagonist; Microdialysis; Venlafaxine; Antidepressant (Hatanaka, K.-i. (395) 31)